Posted On: 05/19/2013 12:22:24 PM
Post# of 72441
Agreed with kelt and Ms Seel. All is well, but the silence is deafening. Perhaps Leo is just slammed with work (most likely), but perhaps he is on to something big. You make a good point kelt. What would cause him not to show in front of all that big money at IDEAS? I am excited about the possibilities. Big oharma has been watching this drug closely for years. They know exactly what its capable of. They know the trial is 7 months in and full speed ahead (although admittedly slower than us crazy shareholders would prefer).
They also know that so far, so good on the safety side. That is huge in itself. We often lose sight of that, because as investors, IMO we have lost perspective on how much we are getting out of his P1 trial. Safety in itself is a huge win, as it lays the solid foundation and groundwork for all other combination trials to hit the ground running hard once MTD is established at Dana Farber. We are building a CTIX mansion, and right now Dana Farber is pouring the foundation and waiting for the concrete (data) to harden.
Who's to say that Pfizer, the big kid on the block, or Celgene, the dark horse candidate, haven't already seen enough from a safety standpoint to dip their feet in the water? Think about it, say they even agree to do a very basic JV to help fund and expand trials, say they drop 500 million (just a random WAG number) to make it happen in some way, shape, or form. Just something to lay the groundwork with Leo to give them a leg up on possibly owning the drug down the road. Celgene or Pfizer taking a 500 million dollar gamble on Kevetrin is like one of us deciding to take a 5 dollar gamble on the powerball. If we dont win, who cares? Won't even make a dent in our bottom line. Im sure big pharma feels the same and that is why i believe there may be some type of "entry level" JV in the works, hence the silence from the CEO. Just IMO of course, it very well could be as simple as Leo is working 12-14 hours a day to run a company that has a hell of a lot going for it.
But I don't believe that, I think great things are coming, and soon after DF gets to share their good work with the world.
They also know that so far, so good on the safety side. That is huge in itself. We often lose sight of that, because as investors, IMO we have lost perspective on how much we are getting out of his P1 trial. Safety in itself is a huge win, as it lays the solid foundation and groundwork for all other combination trials to hit the ground running hard once MTD is established at Dana Farber. We are building a CTIX mansion, and right now Dana Farber is pouring the foundation and waiting for the concrete (data) to harden.
Who's to say that Pfizer, the big kid on the block, or Celgene, the dark horse candidate, haven't already seen enough from a safety standpoint to dip their feet in the water? Think about it, say they even agree to do a very basic JV to help fund and expand trials, say they drop 500 million (just a random WAG number) to make it happen in some way, shape, or form. Just something to lay the groundwork with Leo to give them a leg up on possibly owning the drug down the road. Celgene or Pfizer taking a 500 million dollar gamble on Kevetrin is like one of us deciding to take a 5 dollar gamble on the powerball. If we dont win, who cares? Won't even make a dent in our bottom line. Im sure big pharma feels the same and that is why i believe there may be some type of "entry level" JV in the works, hence the silence from the CEO. Just IMO of course, it very well could be as simple as Leo is working 12-14 hours a day to run a company that has a hell of a lot going for it.
But I don't believe that, I think great things are coming, and soon after DF gets to share their good work with the world.
(0)
(0)Scroll down for more posts ▼
